FindTrial
Sign In

A randomized, double-blind, placebo-controlled study of daridorexant treatment in adolescents with enuresis: proof-of-concept.

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521443-20-00
Enrollment
20
Registered
2025-07-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturnal enuresis

Brief summary

Change in wet nights/week.

Detailed description

Nocturnal urine production., Bladder capacity (maximum voided volume)., Nocturnal bladder capacity., Adverse events., Termination of the treatment., Number of participants with full- and partial response

Interventions

DRUGQUVIVIQ 25 mg film-coated tablets
DRUGConvex tablet coated with DB Caps®
DRUGsize B
DRUGGray Opaque from Lonza Capsugel.

Sponsors

Region Midtjylland
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Change in wet nights/week.—

Secondary

MeasureTime frame
Nocturnal urine production., Bladder capacity (maximum voided volume)., Nocturnal bladder capacity., Adverse events., Termination of the treatment., Number of participants with full- and partial response—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026